 "Bharat Biotech follows SII, reduces Covaxin price to Rs 400 for states")
Bharat Biotech on Thursday reduced the price of Covaxin, an indigenously developed Covid-19 vaccine, by 33 per cent for state governments to Rs 400 a dose. Earlier, it was priced at Rs 600 a dose. The prices for the international market ($15-20 a dose) and private hospitals (Rs 1,200 a dose) remain the same as previously announced.
The move came a day after Serum Institute of India cut the price of its Covishield vaccine to Rs 300 from Rs 400 a dose for states. On Monday, the Centre had asked the two vaccine makers to reduce their prices, following objections by states over the differential pricing.
Bharat Biotech said that “recognising the enormous challenges to the public healthcare system”, it had decided to make Covaxin available for state governments for Rs 400 a dose.
he Hyderabad-based firm reiterated that the approach to pricing was determined by internally funded product development, several operationally intensive BSL -3 manufacturing facilities.
The Centre has sanctioned Rs 1,500 crore as suppliers’ credit for Bharat Biotech to buy future doses of vaccines. It has also received a grant of over Rs 130 crore from the Centre to augment its production capacities to 100 million doses per month by September. At present, the company is able to produce 10 million doses a month and a ramp-up plan is in the works.
The move came a day after Serum Institute of India cut the price of its Covishield vaccine to Rs 300 from Rs 400 a dose for states. On Monday, the Centre had asked the two vaccine makers to reduce their prices, following objections by states over the differential pricing.
Bharat Biotech said that “recognising the enormous challenges to the public healthcare system”, it had decided to make Covaxin available for state governments for Rs 400 a dose.
he Hyderabad-based firm reiterated that the approach to pricing was determined by internally funded product development, several operationally intensive BSL -3 manufacturing facilities.
The Centre has sanctioned Rs 1,500 crore as suppliers’ credit for Bharat Biotech to buy future doses of vaccines. It has also received a grant of over Rs 130 crore from the Centre to augment its production capacities to 100 million doses per month by September. At present, the company is able to produce 10 million doses a month and a ramp-up plan is in the works.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%